{
  "emaEpar": [],
  "fdaDrugLabel": [
    {
      "brand": "Daunorubicin Hydrochloride",
      "indication": "INDICATIONS AND USAGE Daunorubicin hydrochloride in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.",
      "manufacturer": "Hikma Pharmaceuticals USA Inc.",
      "splSetId": "227784a8-ce68-4dd4-8ac5-a65265969677"
    },
    {
      "brand": "daunorubicin hydrochloride",
      "indication": "INDICATIONS AND USAGE Daunorubicin hydrochloride injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.",
      "manufacturer": "Teva Parenteral Medicines, Inc.",
      "splSetId": "29fe455e-f177-4b0e-99fb-60a53016db72"
    },
    {
      "brand": "Daunorubicin Hydrochloride",
      "indication": "INDICATIONS AND USAGE Daunorubicin hydrochloride injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.",
      "manufacturer": "Hisun Pharmaceuticals USA, Inc.",
      "splSetId": "9705fa12-499e-41a3-8fb4-f6df0858b851"
    }
  ],
  "id": "Daunorubicin_Hydrochloride",
  "nciThesaurus": {
    "casRegistry": "23541-50-6",
    "chebiId": "",
    "chemicalFormula": "C27H29NO10.HCl",
    "definition": "The hydrochloride salt of an anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin.  Daunorubicin exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis.",
    "fdaUniiCode": "UD984I04LZ",
    "identifier": "C1583",
    "preferredName": "Daunorubicin Hydrochloride",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C1594"
    ],
    "synonyms": [
      "5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)-, hydrochloride",
      "5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, hydrochloride, (8S-cis)-(9CI)",
      "CERUBIDINE",
      "Cerubidin",
      "Cerubidine",
      "Cloridrato de Daunorubicina",
      "DAUNORUBICIN HYDROCHLORIDE",
      "Daunoblastin",
      "Daunoblastina",
      "Daunoblastine",
      "Daunomycin Hydrochloride",
      "Daunomycin hydrochloride",
      "Daunomycin, hydrochloride",
      "Daunorubicin Hydrochloride",
      "Daunorubicin hydrochloride",
      "Daunorubicin.HCl",
      "Daunorubicini Hydrochloridum",
      "FI-6339",
      "L-lyxo-Hexopyranoside, 3beta-acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-metldioxo-1a-naphthacenyl 3-amino-2,3,6-trideoxy-,alpha-,hydrochloride",
      "Ondena",
      "RP-13057",
      "Rubidomycin Hydrochloride",
      "Rubilem",
      "daunomycin hydrochloride",
      "daunorubicin hydrochloride"
    ]
  }
}